BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38637138)

  • 1. Detecting Metastatic Patterns of Oligometastatic Breast Cancer: A Comparative Analysis of
    Moser R; Pfeiffer S; Cala L; Klein E; Kiechle M; Behzadi ST; Fallenberg E; Combs SE; Weber W; Borm KJ
    J Nucl Med; 2024 Apr; ():. PubMed ID: 38637138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effects of Preoperative (18)F-FDG PET/CT in Breast Cancer Patients in Comparison to the Conventional Imaging Study.
    Choi YJ; Shin YD; Kang YH; Lee MS; Lee MK; Cho BS; Kang YJ; Park JS
    J Breast Cancer; 2012 Dec; 15(4):441-8. PubMed ID: 23346174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing
    Sarikaya I; Sarikaya A
    J Nucl Med Technol; 2019 Jun; 47(2):149-153. PubMed ID: 30413593
    [No Abstract]   [Full Text] [Related]  

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response Monitoring in Metastatic Breast Cancer: A Prospective Study Comparing
    Vogsen M; Harbo F; Jakobsen NM; Nissen HJ; Dahlsgaard-Wallenius SE; Gerke O; Jensen JD; Asmussen JT; Jylling AMB; Braad PE; Vach W; Ewertz M; Hildebrandt MG
    J Nucl Med; 2023 Mar; 64(3):355-361. PubMed ID: 36207136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-body
    Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of 18F-FDG PET/CT in identifying distant metastatic disease missed by conventional imaging in patients with locally advanced breast cancer.
    Manohar K; Mittal BR; Bhoil A; Bhattacharya A; Singh G
    Nucl Med Commun; 2013 Jun; 34(6):557-61. PubMed ID: 23549551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma.
    Vaarwerk B; Breunis WB; Haveman LM; de Keizer B; Jehanno N; Borgwardt L; van Rijn RR; van den Berg H; Cohen JF; van Dalen EC; Merks JH
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012325. PubMed ID: 34753195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical value of PET/CT in identifying patients with oligometastatic/oligoprogressive disease among first-line tyrosine kinase inhibitor-treated advanced EGFR-mutant non-small cell lung cancer: Implications from survival comparisons.
    Xu D; Yu F; Guo T; Zhou Y; Zhang J; Li Y; Jiang S; Mao J; Yang X; Chu L; Chu X; Wang S; Ni J; Zhu Z
    Br J Radiol; 2022 Aug; 95(1136):20220035. PubMed ID: 35611637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4).
    Kroese TE; Bronzwaer S; van Rossum PSN; Schoppman SF; Deseyne PRAJ; van Cutsem E; Haustermans K; Nafteux P; Thomas M; Obermannova R; Mortensen HR; Nordsmark M; Pfeiffer P; Elme A; Adenis A; Piessen G; Bruns CJ; Lordick F; Gockel I; Moehler M; Gani C; Liakakos T; Reynolds JV; Morganti AG; Rosati R; Castoro C; Cellini F; D'Ugo D; Roviello F; Bencivenga M; de Manzoni G; van Berge Henegouwen MI; Hulshoff MCCM; van Dieren J; Vollebergh M; van Sandick JW; Jeene P; Muijs C; Slingerland M; Voncken FEM; Hartgrink H; Creemers GJ; van der Sangen MJC; Nieuwenhuijzen GAP; Berbee M; Verheij M; Wijnhoven B; Beerepoot LV; Mohammad NH; Mook S; Ruurda JP; Kolodziejczyk P; Polkowski WP; Wyrwicz L; Alsina M; Tabernero J; Pera M; Kanonnikoff TF; Cervantes A; Nilsson M; Monig S; Wagner AD; Guckenberger M; Griffiths EA; Smyth E; Hanna GB; Markar S; Chaudry MA; Hawkins MA; Cheong E; van Laarhoven HWM; van Hillegersberg R;
    Eur J Cancer; 2024 Jun; 204():114062. PubMed ID: 38678762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic performance of
    Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
    Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Pattern of Metastatic Breast Cancer: A Prospective Head-to-Head Comparison of [
    Gram-Nielsen R; Christensen IY; Naghavi-Behzad M; Dahlsgaard-Wallenius SE; Jakobsen NM; Gerke O; Jensen JD; Ewertz M; Hildebrandt MG; Vogsen M
    J Imaging; 2023 Oct; 9(10):. PubMed ID: 37888329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of [
    Deleu AL; Laenen A; Decaluwé H; Weynand B; Dooms C; De Wever W; Jentjens S; Goffin K; Vansteenkiste J; Van Laere K; De Leyn P; Nackaerts K; Deroose CM
    EJNMMI Res; 2022 May; 12(1):28. PubMed ID: 35524900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial.
    Verghote F; Poppe L; Verbeke S; Dirix P; Albersen M; De Meerleer G; Berghen C; Ost P; Villeirs G; De Visschere P; De Man K; De Maeseneer D; Rottey S; Van Praet C; Decaestecker K; Fonteyne V
    BMC Cancer; 2021 Oct; 21(1):1113. PubMed ID: 34663254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Performance of FDG-PET/CT Scan as Compared to US-Guided FNA in Prediction of Axillary Lymph Node Involvement in Breast Cancer Patients.
    Assi HI; Alameh IA; Khoury J; Bou Zerdan M; Akiki V; Charafeddine M; El Saheb GI; Sukhon F; Sbaity E; Baydoun S; Shabb N; Berjawi G; Haidar MB
    Front Oncol; 2021; 11():740336. PubMed ID: 34660301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of dual-time-point 18F-FDG PET/CT for identifying axillary lymph node metastasis in breast cancer patients.
    Choi WH; Yoo IR; O JH; Kim SH; Chung SK
    Br J Radiol; 2011 Jul; 84(1003):593-9. PubMed ID: 21081574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of [
    Yang Q; Huang D; Wu J; Zhong H; Han Y; Jiang H; Chen Y; Chen G; Zhan X; Zhou P
    Eur Radiol; 2024 Feb; 34(2):1077-1085. PubMed ID: 37589901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors affecting the accuracy of
    Kutluturk K; Simsek A; Comak A; Gonultas F; Unal B; Kekilli E
    Niger J Clin Pract; 2019 Jan; 22(1):63-68. PubMed ID: 30666022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-[
    Vogsen M; Naghavi-Behzad M; Harbo FG; Jakobsen NM; Gerke O; Asmussen JT; Nissen HJ; Dahlsgaard-Wallenius SE; Braad PE; Jensen JD; Ewertz M; Hildebrandt MG
    Sci Rep; 2023 Apr; 13(1):5552. PubMed ID: 37019987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.